# Versant Ventures: portfolio, investments and team

> Versant Ventures is a vc firm based in United States. 256 investments on record, 7 in the last 12 months, latest Oct 2026.

Source: https://millionrounds.com/fund/versant-ventures (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# Versant Ventures

Last cheque observed Oct 2026; 256 cheques on record.

Email

Deploying now New fund $5.0M, May 2024 VC firm

Seed Series A Series B Connected Health E-health Healthier Living

Follow Versant Ventures and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fversant-ventures)

Deploying now

**54%** of best year **7** **cheques in 12 months**, 256 on record

Since the last cheque **12** days **00** hrs **00** min **00** sec

Median round **$63M** Cheque size, as they say **$100K – $5.0M** Rounds led **0 of 256** Sole investor **24 rounds** Exits **29 from the portfolio** Mostly in **United States, 68%**

Pitch Versant Ventures

## Versant Ventures highlights

- 01 7 cheques in the last 12 months
- 02 Mostly Series B and Series A: 55% of its rounds
- 03 Sole investor in 24 rounds, median $20M
- 04 29 exits from the portfolio

## What they do

> Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. From their own website

- **Type:** VC firm (from a list, unverified)
- **Cheque size:** $100K – $5.0M as they say
- **Stages:** Seed Series A Series B Growth Pre-IPO
- **Sectors:** Connected Health E-health Healthier Living
- **Based in:** San Francisco, United States
- **Cold pitches:** Not accepted

## The record

Every round we can evidence, newest first **256 appearances**

- **2026** 4 rounds
- **Oct** **[Nouscom](https://millionrounds.com/company/nouscom)** Series D · CH · Revelation Partners **$135M** With 14 others
- **Sept** **[Tempest Therapeutics](https://millionrounds.com/company/tempest-therapeutics)** US **$2.5M** With 4 others
- **Mar** **[CRISPR Therapeutics](https://millionrounds.com/company/crispr-therapeutics)** Debt · US **$550M** With 2 others
- **Jan** **[Monte Rosa Therapeutics](https://millionrounds.com/company/monte-rosa-therapeutics)** CH **$300M** With 5 others
- **2025** 8 rounds
- **Dec** **[Contineum Therapeutics](https://millionrounds.com/company/contineum-therapeutics)** US **$99M** With 3 others
- **Nov** **[Gate Bioscience](https://millionrounds.com/company/gate-bioscience)** Series B · US **$65M** With 5 others
- **Nov** **[Dayra Therapeutics](https://millionrounds.com/company/dayra-therapeutics)** Venture · US **$20M** Sole investor
- **Sept** **[Dualitas Therapeutics](https://millionrounds.com/company/dualitas-therapeutics)** Series A · US **$65M** With 4 others
- **Sept** **[AllRock Bio](https://millionrounds.com/company/allrock-bio)** Series A · US **$50M** Sole investor
- **Apr** **[Granite Bio](https://millionrounds.com/company/granite-bio)** Series B · US · Silicon Canals **$70M** With 3 others
- **Jan** **[Helicore Biopharma](https://millionrounds.com/company/helicore-biopharma)** Series A · US **$65M** With 3 others
- **Jan** **[Light Horse Therapeutics](https://millionrounds.com/company/light-horse-therapeutics)** Series A · US **$62M** With 2 others
- **2024** 12 rounds
- **Dec** **[Antag Therapeutics](https://millionrounds.com/company/antag-therapeutics)** Series A · DK **$84M** With 4 others
- **Dec** **[Borealis Biosciences](https://millionrounds.com/company/borealis-biosciences)** Series A · CA **$30M** With 1 other
- **Sept** **[858 Therapeutics](https://millionrounds.com/company/858-therapeutics)** Series B · US **$50M** With 4 others
- **Aug** **[Kate Therapeutics](https://millionrounds.com/company/kate-therapeutics)** Series B · US **$22M** Sole investor
- **Jul** **[LENZ Therapeutics](https://millionrounds.com/company/lenz-therapeutics)** US **$30M** With 4 others
- **Jun** **[Santa Ana Bio](https://millionrounds.com/company/santa-ana-bio)** Series B · US **$125M** With 4 others
- **Jun** **[Bright Peak Therapeutics](https://millionrounds.com/company/bright-peak-therapeutics)** Series C · CH **$90M** With 4 others
- **May** **[SixPeaks Bio](https://millionrounds.com/company/sixpeaks-bio)** Debt · CH **$80M** Sole investor
- **Apr** **[ViaLase](https://millionrounds.com/company/vialase)** Series C · US **$40M** Sole investor
- **Mar** **[Nouscom](https://millionrounds.com/company/nouscom)** Series C · CH **$7.6M** With 4 others
- **Feb** **[Firefly Bio](https://millionrounds.com/company/firefly-bio)** Series A · US **$94M** With 1 other
- **Jan** **[Enterprise Therapeutics](https://millionrounds.com/company/enterprise-therapeutics)** Series B · GB **$33M** With 3 others
- **2023** 6 rounds
- **Nov** **[Halio](https://millionrounds.com/company/halio)** Venture · US **$70M** With 3 others
- **Sept** **[Tentarix Biotherapeutics](https://millionrounds.com/company/tentarix-biotherapeutics)** Series B · US **$35M** With 1 other
- **Jul** **[Nexo Therapeutics](https://millionrounds.com/company/nexo-therapeutics)** Series A · US **$60M** With 2 others
- **Apr** **[Abdera Therapeutics](https://millionrounds.com/company/abdera-therapeutics)** Series B · CA **$142M** With 3 others
- **Feb** **[Capsida Biotherapeutics](https://millionrounds.com/company/capsida-biotherapeutics)** Venture · US **Undisclosed** With 1 other
- **Jan** **[Belharra Therapeutics](https://millionrounds.com/company/belharra-therapeutics)** Series A · US **$50M** Sole investor
- **2022** 9 rounds
- **Dec** **[Launchpad Therapeutics](https://millionrounds.com/company/launchpad-therapeutics)** Venture · US **$10M** With 1 other
- **Nov** **[Jnana Therapeutics](https://millionrounds.com/company/jnana-therapeutics)** Series C · US **$107M** With 4 others
- **Nov** **[iECURE](https://millionrounds.com/company/iecure)** Series A · US **$65M** With 2 others
- **Oct** **[Anokion](https://millionrounds.com/company/anokion)** Venture · CH **$35M** With 1 other
- **Oct** **[Nested Therapeutics](https://millionrounds.com/company/nested-therapeutics)** Series A · US **$90M** With 4 others
- **Sept** **[Venatorx Pharmaceuticals](https://millionrounds.com/company/venatorx-pharmaceuticals)** Venture · US **$25M** With 1 other
- **Aug** **[Vector BioPharma](https://millionrounds.com/company/vector-biopharma)** Series A · CH **$30M** Sole investor
- **May** **[Chinook Therapeutics](https://millionrounds.com/company/chinook-therapeutics)** CA **$105M** With 3 others
- **Apr** **[Cimeio Therapeutics](https://millionrounds.com/company/cimeio-therapeutics)** Series A · CH **$50M** Sole investor
- **2021** 9 rounds
- **Dec** **[CODA Biotherapeutics](https://millionrounds.com/company/coda-biotherapeutics)** Venture · US **$28M** With 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **23 named**

AM **Alex Mayweg** Managing Director of the Ultimate General Partner i Filing they signed

AV **Alexander Volker Mayweg** Managing Director, Versant Ventures (Switzerland) Gmbh i Form ADV

BN **Barbara N. Lubash** Managing Director of the General Partner of the Issuser i Filing they signed

BJ **Bradley J. Bolzon** Manager of the General Partner of the General Partner of Parallel i Filing they signed

BG **Brian G. Atwood** Managing Member, Versant Venture Management, LLC i Form ADV

CD **Camille D. Samuels** Managing Director i Filing they signed

CD **Carlo Dante Rizzuto** Managing Director of the Ultimate General Partner i Filing they signed

CM **Charles M. Warden** Managing Member, Versant Venture Management, LLC i Form ADV

CO **Clare Ozawa** Managing Director of the Ultimate General Partner i Filing they signed

DB **Donald B. Milder** Managing Member, Versant Venture Management, LLC i Form ADV

JC **Jerel Clayton Davis** Director of the General Partner of Voyageurs and Manager of the General Partner of the General Partner of Parallel i Filing they signed

KL **Kirk L. Nielsen** Manager of the General Partner of the General Partner of Parallel i Filing they signed

MM **Markus Michael Enzelberger** Director of Versant Ventures (Switzerland) Gmbh i Form ADV

MB **Max Benjamin Eisenberg** General Counsel, Versant Venture Management, LLC i Form ADV

RB **Rebecca B. Robertson** Managing Director i Filing they signed

RD **Richard D. Van Doren** CFO, Versant Venture Management, LLC i Form ADV

RL **Robin L. Praeger** Director and President of the General Partner of Voyageurs and Manager of the General Partner of the General Partner of Parallel i Filing they signed

RA **Ross A. Jaffe** Managing Member, Versant Venture Management, LLC i Form ADV

SC **Sam Colella** Manager i Filing they signed

SD **Samuel D. Colella** Managing Director of the General Partner of the Isuer i Filing they signed

TF **Thomas F. Woiwode** Manager of the General Partner of the General Partner of Parallel i Filing they signed

TL **Tom L. Woiwode** Managing Director i Filing they signed

WJ **William J. Link** Managing Member, Versant Venture Management, LLC i Form ADV

We also hold **61** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$3.9B** gross assets of its funds Oct 2026

**Exempt** reporting adviser venture or small private funds

- **Legal name:** Versant Venture Management, LLC
- **SEC number:** CRD 161130

## What they claim to have backed

From their own portfolio page (on their website)

**0** of 1 we have independently watched raise

Wearefine

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

## Exits from the portfolio

Companies it backed that were later bought or listed **29 in all**

**[Novira Therapeutics](https://millionrounds.com/company/novira-therapeutics)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **Undisclosed** Nov 2015

**[Skylight Healthcare Systems](https://millionrounds.com/company/skylight-healthcare-systems)** Bought by GetWellNetwork, Inc. **Undisclosed** Sept 2015

**[Twelve](https://millionrounds.com/company/twelve)** Bought by [Medtronic](https://millionrounds.com/fund/medtronic) **$458M** Aug 2015

**[CardiAQ Valve Technologies](https://millionrounds.com/company/cardiaq-valve-technologies)** Bought by [Edwards Lifesciences](https://millionrounds.com/fund/edwards-lifesciences) **$350M** Jul 2015

**[Kythera Biopharmaceuticals](https://millionrounds.com/company/kythera-biopharmaceuticals)** Bought by [Allergan](https://millionrounds.com/fund/allergan) **$2.1B** Jun 2015

**[WaveTec Vision](https://millionrounds.com/company/wavetec-vision)** Bought by [Alcon](https://millionrounds.com/fund/alcon) **Undisclosed** Sept 2014

**[Trius Therapeutics](https://millionrounds.com/company/trius-therapeutics)** Listed **Undisclosed** Jul 2013

**[Trius Therapeutics](https://millionrounds.com/company/trius-therapeutics)** Bought by [Cubist Pharmaceuticals](https://millionrounds.com/fund/cubist-pharmaceuticals) **$707M** Jul 2013

**[Five Prime Therapeutics](https://millionrounds.com/company/five-prime-therapeutics)** Listed **Undisclosed** Jul 2013

**[Okairos](https://millionrounds.com/company/okairos)** Bought by [GlaxoSmithKline](https://millionrounds.com/fund/glaxosmithkline) **$325M** May 2013

**[Cameron Health](https://millionrounds.com/company/cameron-health)** Bought by [Boston Scientific](https://millionrounds.com/fund/boston-scientific) **Undisclosed** Jun 2012

**[Clovis Oncology](https://millionrounds.com/company/clovis-oncology)** Listed **$130M** Nov 2011

**[Calypso Medical](https://millionrounds.com/company/calypso-medical)** Bought by Varian Medical Systems **Undisclosed** Sept 2011

**[Amira Pharmaceuticals](https://millionrounds.com/company/amira-pharmaceuticals)** Bought by [Bristol-Myers Squibb](https://millionrounds.com/fund/bristol-myers-squibb) **$325M** Jul 2011

**[Synosia Therapeutics](https://millionrounds.com/company/synosia-therapeutics)** Bought by Biotie Therapies **$122M** Jan 2011

**[LensX Lasers](https://millionrounds.com/company/lensx-lasers)** Bought by [Alcon](https://millionrounds.com/fund/alcon) **Undisclosed** Jul 2010

**[Concuity](https://millionrounds.com/company/concuity)** Bought by The Advisory Board Company **Undisclosed** Mar 2010

**[Acclarent](https://millionrounds.com/company/acclarent)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **$785M** Dec 2009

**[Confirma](https://millionrounds.com/company/confirma)** Bought by Merge Healthcare **Undisclosed** Aug 2009

**[NeoGuide Systems](https://millionrounds.com/company/neoguide-systems)** Bought by Intuitive Surgical **Undisclosed** Jun 2009

The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$5.0M**

raised in May 2024

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Seed Series A Series B

Median round joined **$63M** the round, not its cheque Alone, median **$20M**

Led 0 of 256 rounds **0%**

- **Said size:** $100K – $5.0M
- **Sole investor:** 24 rounds
- **Last cheque:** Oct 2026
- **Exits:** 29 from the portfolio

Rounds by stage said on their site

- Series B said *63*
- Series A said *59*
- Series C *40*
- Venture *37*
- Series D *24*
- Seed said *-*
- Growth said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [5AM Ventures](https://millionrounds.com/fund/5am-ventures) 26
- [New Enterprise Associates](https://millionrounds.com/fund/new-enterprise-associates) 26
- [Domain Associates](https://millionrounds.com/fund/domain-associates) 25
- [Accuitive Medical Ventures](https://millionrounds.com/fund/accuitive-medical-ventures) 17
- [ARCH Venture Partners](https://millionrounds.com/fund/arch-venture-partners) 16
- [OrbiMed](https://millionrounds.com/fund/orbimed) 16

**Pitching Versant Ventures?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Versant Ventures. A count of rooms they were both in, not a relationship either has claimed.

[**5AM Ventures** VC firm **26** rounds together](https://millionrounds.com/fund/5am-ventures)[**New Enterprise Associates** VC firm **26** rounds together](https://millionrounds.com/fund/new-enterprise-associates)[**Domain Associates** VC firm **25** rounds together](https://millionrounds.com/fund/domain-associates)[**Accuitive Medical Ventures** VC firm **17** rounds together](https://millionrounds.com/fund/accuitive-medical-ventures)[**ARCH Venture Partners** VC firm **16** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**OrbiMed** Private equity **16** rounds together](https://millionrounds.com/fund/orbimed)[**InterWest Partners** VC firm **15** rounds together](https://millionrounds.com/fund/interwest-partners)[**Venrock** VC firm **15** rounds together](https://millionrounds.com/fund/venrock)[**SV Life Sciences** VC firm **13** rounds together](https://millionrounds.com/fund/sv-life-sciences)[**Frazier Healthcare Partners** Private equity **12** rounds together](https://millionrounds.com/fund/frazier-healthcare-partners)[**Novo Holdings** VC firm **12** rounds together](https://millionrounds.com/fund/novo-ventures)[**Alta Partners** VC firm **10** rounds together](https://millionrounds.com/fund/alta-partners)

## Recently backed

The latest companies Versant Ventures put money into.

[**Nouscom** $135M · Oct 2026](https://millionrounds.com/company/nouscom)[**Tempest Therapeutics** $2.5M · Sept 2026](https://millionrounds.com/company/tempest-therapeutics)[**CRISPR Therapeutics** $550M · Mar 2026](https://millionrounds.com/company/crispr-therapeutics)[**Monte Rosa Therapeutics** $300M · Jan 2026](https://millionrounds.com/company/monte-rosa-therapeutics)[**Contineum Therapeutics** $99M · Dec 2025](https://millionrounds.com/company/contineum-therapeutics)[**Gate Bioscience** $65M · Nov 2025](https://millionrounds.com/company/gate-bioscience)

## Quick answers about Versant Ventures

### What does Versant Ventures invest in?

Versant Ventures invests most often at Series B and Series A (55% of the rounds on record), in sectors such as Connected Health, E-health and Healthier Living.

### How active is Versant Ventures?

256 investments on record, 7 of them in the last 12 months. The most recent was in Oct 2026.

### What has Versant Ventures invested in recently?

Its most recent investments on record: Nouscom (Series D, Oct 2026), Tempest Therapeutics (Undisclosed round, Sept 2026) and CRISPR Therapeutics (Debt, Mar 2026).

### How big are Versant Ventures's cheques?

The median round it joins is $63M. It says it writes cheques of $100K to $5.0M.

### Does Versant Ventures lead rounds?

Rarely, if at all: none of its 256 investments on record names it as the lead.

### Where does Versant Ventures invest?

Most of the companies it backs are in the United States (68%), Switzerland (20%) and Canada (8%).

### Is Versant Ventures investing now?

Yes: it is actively investing, with 7 investments in the last 12 months.

### Who does Versant Ventures invest alongside?

Most often 5AM Ventures (26 rounds together), New Enterprise Associates (26 rounds together) and Domain Associates (25 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=versant-ventures) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=versant-ventures)